Expand ESPR Menu
ESPR MENU

ESPR Latest Press Releases

-- May 26, 2026 --

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026 Globe Newswire 8:00 AM

-- May 14, 2026 --

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- May 13, 2026 --

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026 Globe Newswire 8:00 AM

-- May 6, 2026 --

Halper Sadeh LLC is Investigating Whether SILA, ESPR, CRBG, EQH are Obtaining Fair Deals for their Shareholders Globe Newswire 9:41 PM

-- May 5, 2026 --

Halper Sadeh LLC is Investigating Whether SILA, LSTA, ESPR are Obtaining Fair Deals for their Shareholders Globe Newswire 4:09 PM

-- May 4, 2026 --

Are ESPR, GBTG, MDV, ACR Obtaining Fair Deals for their Shareholders? PRNewswire 2:53 PM
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR Business Wire 11:48 AM

-- May 1, 2026 --

Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders PRNewswire 11:30 AM
ESPR Stock Alert: Halper Sadeh LLC is Investigating Whether Esperion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders Business Wire 9:41 AM
Esperion to be Acquired by ARCHIMED Globe Newswire 7:00 AM

-- April 23, 2026 --

Esperion to Report First Quarter 2026 Financial Results on May 7 Globe Newswire 8:00 AM

-- April 2, 2026 --

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics Globe Newswire 4:05 PM
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst (bumetanide nasal spray) Globe Newswire 4:00 PM

-- March 31, 2026 --

Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference Globe Newswire 8:00 AM

-- March 30, 2026 --

Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL (bempedoic acid) at the American College of Cardiology's Annual Scientific Session 2026 Globe Newswire 8:00 AM

-- March 17, 2026 --

Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session Globe Newswire 8:00 AM

-- March 16, 2026 --

Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia Globe Newswire 6:30 AM

-- March 10, 2026 --

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Globe Newswire 6:00 AM

-- March 3, 2026 --

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst (bumetanide nasal spray) Business Wire 6:00 AM
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst (bumetanide nasal spray) Globe Newswire 6:00 AM

-- February 24, 2026 --

Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10 Globe Newswire 8:00 AM

-- February 18, 2026 --

Esperion to Participate in The 2026 Citizens Life Sciences Conference Globe Newswire 8:00 AM

-- February 17, 2026 --

Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) & NEXLIZET (bempedoic acid & ezetimibe) Prior to April 19, 2040 Globe Newswire 8:00 AM

-- February 11, 2026 --

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Globe Newswire 4:30 PM
Market Data Delayed 15 Minutes